Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04664634 · ClinicalTrials.gov registry record · Phase 3
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
A Phase 3 study of Parkinson Disease and Dysphagia, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04664634: Recruiting Phase 3 study of Parkinson Disease and Dysphagia, sponsored by Northwestern University.
NCT04664634 is a Phase 3 study of Parkinson Disease and Dysphagia that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 60 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04664634, a Phase 3 study of Parkinson Disease and Dysphagia, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.
Primary Outcome
Percent agreement between experimental sensor Gold standard (GS) respiratory inductance plethysmography (RIP) with Inductotrace System®, Ambulatory Monitoring)
Conditions Studied
Interventions
- DEVICE Aria Sensor
Study Locations (1)
Illinois
- Northwestern University - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 3 |
What NCT04664634 shows while recruiting
NCT04664634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Aria Sensor is the first listed.
NCT04664634 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04664634 about?
NCT04664634 is a clinical study titled "A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's". The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.
What is the current status of trial NCT04664634?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-04-01. Estimated completion is 2026-05-31.
What conditions does trial NCT04664634 study?
This clinical trial studies the following conditions: Parkinson Disease, Dysphagia.
What interventions are being tested in trial NCT04664634?
The interventions under investigation include: Aria Sensor (DEVICE).
Who is sponsoring clinical trial NCT04664634?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04664634 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04664634's enrollment target sits among peer trials
60 125th of 297 higher than 154 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
RECRUITING · Phase 3
-
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
Embryonic Dopamine Cell Implants for Parkinson's Disease
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
-
Flexible-Dose Trial in Early Parkinson's Disease (PD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- NCT02114450 · 60 participants · NA
Human-Machine System for the H2 Lower Limb Exoskeleton
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI